It is hard to imagine who is selling at these levels. As the Wedbush report indicates, OMER has several low-risk milestones coming up in the second half of the year. Solid data from the second OMS302 Phase III trial, which is a practical certainty given the results from the first trial, should be enough to push the valuation on this stock above $400M (versus less than $200M today). I used to think when I saw action like this that the "experts"/insiders knew something that was not known to the retail world, but recently I have seen a number of stocks get dragged down for no reason, only to spike sharply when milestones are achieved, so I will continue to average down at these levels.
Yes it is baffling.... the shorts report will be out Thursday and we will see if it went up or down. Shorts have been hurting OMER. This is a very good stock with fantastic potential.... I will buy more when they quit screwing with the stock.